Allergan Plc named Carrie Strom as senior vice president of U.S. Medical Aesthetics, reporting to Chief Commercial Officer Bill Meury.
Strom joined Allergan in 2011, most recently serving as vice president of marketing for plastic surgery and regenerative medicine. She was also vice president of marketing for SkinMedica, leading the skin care product brand’s new e-commerce platform.
Allergan’s medical aesthetics portfolio includes Botox, Juvederm fillers, Natrelle breast implants, regenerative tissue Alloderm, SkinMedica and fat cooling technology CoolSculpting. The unit, which generated $2.4 billion in revenue last year—more than double 2016’s revenue of $1.6 billion—remains a top grosser year-over-year.
David Moatazedi, former senior vice president of the division, is now president and chief executive of Irvine-based Evolus Inc., a medical aesthetics company, which released its first product, an injectable neurotoxin that works similarly to Botox. Evolus’ lead drug candidate is waiting for Food and Drug Administration approval to treat moderate to severe frown lines between the eyebrows.
Meury said Strom will direct the entire commercial operation for U.S. medical aesthetics with a focus on “[raising] consumer awareness and interest for aesthetic treatments.”
Shares of Allergan in the intraday session closed at $146 per share for a $48.8 billion market cap.
